|
|
| 1. |
Abstracts (Part 1 of 23) |
| |
Pathophysiology of Haemostasis and Thrombosis,
Volume 26,
Issue 3,
1996,
Page 1-14
Preview
|
PDF (3292KB)
|
|
ISSN:1424-8832
DOI:10.1159/000217275
出版商:S. Karger AG
年代:1996
数据来源: Karger
|
| 2. |
Abstracts (Part 2 of 23) |
| |
Pathophysiology of Haemostasis and Thrombosis,
Volume 26,
Issue 3,
1996,
Page 15-28
Preview
|
PDF (3094KB)
|
|
ISSN:1424-8832
DOI:10.1159/000317911
出版商:S. Karger AG
年代:1996
数据来源: Karger
|
| 3. |
Abstracts (Part 3 of 23) |
| |
Pathophysiology of Haemostasis and Thrombosis,
Volume 26,
Issue 3,
1996,
Page 29-42
Preview
|
PDF (2873KB)
|
|
ISSN:1424-8832
DOI:10.1159/000317912
出版商:S. Karger AG
年代:1996
数据来源: Karger
|
| 4. |
Abstracts (Part 4 of 23) |
| |
Pathophysiology of Haemostasis and Thrombosis,
Volume 26,
Issue 3,
1996,
Page 43-56
Preview
|
PDF (3046KB)
|
|
ISSN:1424-8832
DOI:10.1159/000317913
出版商:S. Karger AG
年代:1996
数据来源: Karger
|
| 5. |
Abstracts (Part 5 of 23) |
| |
Pathophysiology of Haemostasis and Thrombosis,
Volume 26,
Issue 3,
1996,
Page 57-70
Preview
|
PDF (3042KB)
|
|
ISSN:1424-8832
DOI:10.1159/000317914
出版商:S. Karger AG
年代:1996
数据来源: Karger
|
| 6. |
Abstracts (Part 6 of 23) |
| |
Pathophysiology of Haemostasis and Thrombosis,
Volume 26,
Issue 3,
1996,
Page 71-84
Preview
|
PDF (3055KB)
|
|
ISSN:1424-8832
DOI:10.1159/000317915
出版商:S. Karger AG
年代:1996
数据来源: Karger
|
| 7. |
Abstracts (Part 7 of 23) |
| |
Pathophysiology of Haemostasis and Thrombosis,
Volume 26,
Issue 3,
1996,
Page 85-98
Preview
|
PDF (3058KB)
|
|
ISSN:1424-8832
DOI:10.1159/000317916
出版商:S. Karger AG
年代:1996
数据来源: Karger
|
| 8. |
Abstracts (Part 8 of 23) |
| |
Pathophysiology of Haemostasis and Thrombosis,
Volume 26,
Issue 3,
1996,
Page 99-112
Preview
|
PDF (3365KB)
|
|
ISSN:1424-8832
DOI:10.1159/000317917
出版商:S. Karger AG
年代:1996
数据来源: Karger
|
| 9. |
Abstracts (Part 9 of 23) |
| |
Pathophysiology of Haemostasis and Thrombosis,
Volume 26,
Issue 3,
1996,
Page 113-126
Preview
|
PDF (3078KB)
|
|
ISSN:1424-8832
DOI:10.1159/000317918
出版商:S. Karger AG
年代:1996
数据来源: Karger
|
| 10. |
Can the Haemorrhagic Component of Heparin Be Identified? Or an Attempt at Clean Thinking on a Dirty Drug |
| |
Pathophysiology of Haemostasis and Thrombosis,
Volume 26,
Issue 3,
1996,
Page 117-126
Coenraad Hemker,
Suzette Béguin,
Vijay V. Kakkar,
Preview
|
PDF (4189KB)
|
|
摘要:
Heparin consists of different classes of molecules. We distinguish below-critical-chain length heparin (BCLM, MW 8,000) and ACLM-low (MW 5,400-8,000). Extra large material is abundantly present in unfractionated heparin but is rare in low-molecular-weight (LMW) heparins. We noted that injection of an LMW heparin causes 5- to 10-fold higher plasma levels of ACLM than injection of a clinically equivalent dose of unfractionated heparin (UFH) and proportionally higher inhibitions of the clotting system. So with LMW heparin one can afford higher levels of anticoagulation than with UFH at a lower risk of bleeding. We surmise that this is caused by the virtual absence of the (haemorrhagic) extra-large-molecular-weight fraction from LMW heparins. A laboratory artefact, i.e. the absence of Ca2+ in the anti-factor Xa tests, makes that heparin mixtures that lack extra large heparin molecules show a (spuriously) high ratio of anti-factor Xa activity over anti-thrombin activity. So the correlation between a high aXa/alla ratio and a favourable ratio of antithrombotic effect over bleeding is not necessarily caused by the presence of BCLM. In fact BCLM is a poor anticoagulant; in mixtures of ACLM and BCLM, ACLM causes by far the larger part of the anticoagulant effect. We surmise that the LMW fraction of ACLM is the active anticoagulant component in any heparin preparation and, isolated, would make a proper third-generation heparin.
ISSN:1424-8832
DOI:10.1159/000217197
出版商:S. Karger AG
年代:1996
数据来源: Karger
|
|
首页
